Advertisement

Treatment of chronic stable angina pectoris with gallopamil

  • D. Scrutinio
  • S. Iliceto
  • R. Lagioia
  • D. Accettura
  • N. Preziusi
  • F. Mastropasqua
  • A. Chiddo
  • P. Rizzon
Conference paper

Abstract

In the last few years the number of calcium antagonists available for treatment has increased rapidly since these drugs were shown to be effective in the treatment of stable and unstable angina pectoris. Gallopamil is a new calcium antagonist which appears to be three to four times more potent in animals than verapamil (3,4). About 90% of the dose of gallopamil is absorbed and its bioavailability is about 25% (21). Studies in patients give a mean half-life of 2.8 to 4.8 hours (21), with the concentrations of the unchanged substance peaking one to 2 hours after administration (20). After intravenous administration, this drug dilates the arteries and veins (5, 14), reduces peripheral arterial resistance and the work of the heart (−13%), and myocardial oxygen uptake (−10%), (12). It also dilates the epicardial coronary vessels and prevents vasospasm (10, 11): Gallopamil reduces sino-atrial node excitability and slows conduction in the AV node (4, 6).

Keywords

Exercise Test Angina Pectoris Calcium Antagonist Anginal Symptom High Average Level 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Alderman EL, Davies RO, Crowley JJ et al. (1975) Dose response effectiveness of Propranolol for the treatment of angina pectoris, Circulation 51:964–975PubMedGoogle Scholar
  2. 2.
    Anderson JL, Wagner JM, Datz FL, Christian PE, Bray BE, Taylor AT (1984) Comparative effects of Diltiazem, Propranolol and Placebo on exercise performance using radionuclide ventriculography in patients with symptomatic coronary artery disease: results of a double-blind, randomized, crossover study. Am Heart J 107:698–706.PubMedCrossRefGoogle Scholar
  3. 3.
    Fleckenstein A, Tritthart H, Fleckenstein B, Herbst A, Grün G (1969) Eine neue Gruppe kompetitiver Ca++-Antagonisten (Iproveratril, D 600, Prenylamin) mit starken Hemmeffekten auf die elektromechanische Koppelung im Warmblutmyokard. Pflügers Arch Ges Physiol 307:R25Google Scholar
  4. 4.
    Fleckenstein A, Fleckenstein B, Späth F, Byon YK (1984) Gallopamil (D 600) — a calcium antagonist of high potency and specifiCity. Effects on the myocardium and pacemakers. In: Kaltenbach M, Hopf R (eds) Gallopamil. Pharmacological and clinical profile of a calcium antagonist. Springer, Berlin Heidelberg New York Tokyo, pp. 1–32Google Scholar
  5. 5.
    Fleckenstein-Grün G, Fleckenstein A (1984) Blockade of the Ca++-dependent bioelectrical automatiCity and electromechanical coupling of smooth muscle cells by gallopamil (D 600). In: Kaltenbach M, Hopf R (eds) Gallopamil. Pharmacological and clinical profile of a calcium antagonist. Springer, Berlin Heidelberg New York Tokyo, pp. 33–48Google Scholar
  6. 6.
    Fleckenstein A (1980) Steuerung der myokardialen Kontraktilität, ATP-Spaltung, Atmungsinten-sität und Schrittmacherfunktion durch Calcium-Ionen-Wirkungsmechanismus der Calcium-Antagonisten. In: Fleckenstein A, Roskamm H (eds) Calcium-Antagonisten. Springer, Berlin Heidelberg New York, pp. 1–28CrossRefGoogle Scholar
  7. 7.
    Frishman WH, Klein NA, Strom JA, Willens H, Lejemtel TH, Jentzer J, Siegel L, Klein P, Kirschen N, Silverman R, Pollack S, Doyle R, Kirsten E, Sonnenblick EH (1982) Superiority of Verapamil to Propranolol in stable angina pectoris: a double-blind, randomized crossover trial. Circulation 65 (Suppl):51–59Google Scholar
  8. 8.
    Hopf R, Drews H, and Kaltenbach M (1984) Anti-anginal effect of gallopamil as compared with nifedipine. In: Kaltenbach M, Hopf R (eds) Gallopamil. Pharmacological and clinical profile of a calcium antagonist. Springer, Berlin Heidelberg New York Tokyo, pp. 123–131Google Scholar
  9. 9.
    Khurmi NS, O’Hara MJ, Bowles MJ, Bala Subramanian V, and Raftery EB (1984) Randomized double-blind comparison of Gallopamil and Propranolol in stable angina pectoris. Am J Cardiol 53:684–688PubMedCrossRefGoogle Scholar
  10. 10.
    Kohlhardt M, Bauer B, Krause H, Fleckenstein A (1972) Differentiation of the transmembrane Na+ and Ca++ channel in mammalian cardiac fibres by the use of specific inhibitors. Pflügers Arch Ges Physiol 335:309CrossRefGoogle Scholar
  11. 11.
    Kovách AGB, Ligeti L, Bakos M, Rubanyi G, Koller A (1984) Studies in vitro and in vivo on the effects of gallopamil on coronary vessels. In: Kaltenbach M, Hopf R (eds) Gallopamil. Pharmacological and clinical profile of a calcium antagonist. Springer, Berlin Heidelberg New York Tokyo, pp. 58–65Google Scholar
  12. 12.
    Lehmann HU, Taegener-Torge C, Witt E, Beck OA, Hochrein M (1979) Antiarrhythmischer Wirkungsvergleich zwischen Gallopamil (D 600) und Verapamil. Angiocard 2:103–111Google Scholar
  13. 13.
    Mitrović K, Nimelä L, Neuss N, and Schlepper M (1984): Antianginal effect of the calcium antagonist gallopamil. In: Kaltenbach M, Hopf R (eds) Gallopamil. Pharmacological and clinical profile of a calcium antagonist. Springer, Berlin Heidelberg New York Tokyo, pp. 107–113Google Scholar
  14. 14.
    Raschack M, Gries J, Bühler V, Maurer R (1984) Studies of the cardiovascular effects of gallopamil. In: Kaltenbach M, Hopf R (eds) Gallopamil. Pharmacological and clinical profile of a calcium antagonist. Springer, Berlin Heidelberg New York Tokyo, pp. 72–80Google Scholar
  15. 15.
    Robertson RM, Wood AJJ, Vaughan WK, and Robertson D (1982) Exacerbation of vasotonic angina pectoris by Propranolol. Circulation 65:281–285PubMedCrossRefGoogle Scholar
  16. 16.
    Sadick NN, Tan ATH, Fletcher PJ, Morris J, Kelly DT (1982) A double-blind randomized trial of Propranolol and Verapamil in the treatment of effort angina. Circulation 66:574–579PubMedCrossRefGoogle Scholar
  17. 17.
    Sesto M, Ivancić R, Custović F (1984) The effect of gallopamil on the haemodynamics of patients with coronary heart disease. In: Kaltenbach M, Hopf R (eds) Gallopamil. Pharmacological and clinical profile of a calcium antagonist. Springer, Berlin Heidelberg New York Tokyo, pp. 94–99Google Scholar
  18. 18.
    Smoker PE, MacAlpin RN, Alvaro A, Kattus AA (1972) Reproducibility of a multi-stage near maximal treadmill test for exercise tolerance in angina pectoris. Circulation 48:346Google Scholar
  19. 19.
    Starling MR, Moody M, Crawford MH, Levi B, O’Rourke RA (1984) Repeat treadmill exercise testing: variability of results in patients with angina pectoris. Am Heart J 107:298–303PubMedCrossRefGoogle Scholar
  20. 20.
    Stieren B, Bühler V, Hege HG, Hollmann M, Neuss H, Schlepper M, and Weymann J (1984) Pharmacokinetics and metabolism of gallopamil. In: Kaltenbach M and Hopf R (eds) Gallopamil. Pharmacological and clinical profile of a calcium antagonist. Springer, Berlin Heidelberg New York Tokyo, pp. 88–93Google Scholar
  21. 21.
    Sučić MJ, Bühler V, Kehrhahn OH and Stieren B (1980) Zur Pharmakokinetik und Pharmakody-namik von Gallopamil. Report VP/FMK/FMH 8005 dated 28. 10. 80. Medical Research and Development Department, Pharmaceuticals Division, BASF AktiengesellschaftGoogle Scholar
  22. 22.
    Sučić MJ, Schiemann J (1984) Results of an open multicentre study with 455 patients with coronary heart disease, treated with gallopamil for 1 year. In: Kaltenbach M, Hopf R (eds) Gallopamil, Pharmacological and clinical profile of a calcium antagonist. Springer, Berlin Heidelberg New York Tokyo, pp. 132–135Google Scholar
  23. 23.
    Theisen F, Jahrmärker H (1984) Effect of gallopamil (D 600) on the ECG during exercise in coronary heart disease. In: Kaltenbach M, Hopf R (eds) Gallopamil. Pharmacological and clinical profile of a calcium antagonist. Springer, Berlin Heidelberg New York Tokyo, pp. 117–122Google Scholar
  24. 24.
    Zar J (1974) Biostatistical Analysis. Englewood Cliffs, New York, Prentice HallGoogle Scholar

Copyright information

© Dr. Dietrich Steinkopff Verlag GmbH & Co. KG, Darmstadt 1989

Authors and Affiliations

  • D. Scrutinio
    • 1
    • 3
  • S. Iliceto
    • 2
  • R. Lagioia
    • 1
  • D. Accettura
    • 1
  • N. Preziusi
    • 1
  • F. Mastropasqua
    • 1
  • A. Chiddo
    • 1
    • 2
  • P. Rizzon
    • 1
    • 2
  1. 1.Medical Rehabilitation Centre, Department of Cardiology“Clinica del Lavoro” Foundation, Hospital and Research InstituteCassano Murge, BariItaly
  2. 2.Department of CardiologyUniversity of BariItaly
  3. 3.Divisone di CardiologiaPoliclinico UniversitarioBariItaly

Personalised recommendations